Who is leading this study?
The University of Western Australia, the Sir Charles Gairdner Hospital, the George Institute for Global Health and the University Of Edinburgh
This trial is being co-led by Professor Graeme Hankey from the University of Western Australia and Sir Charles Gairdner Hospital and Professor Craig Anderson from the George Institute for Global Health.
Complete the questionnaire to see if you qualify
What is the ASPIRING clinical trial?
The “Antiplatelet Secondary Prevention International Randomised trial after intracerebral haemorrhage (ASPIRING)” Is an international research collaboration led by medical specialists (neurologists) from the University of Western Australia and Sir Charles Gairdner Hospital, Perth, Western Australia; The George Institute for Global Health, Sydney and China; and the University Of Edinburgh, Scotland, UK.
The aim of the trial is to investigate if single antiplatelet therapy (a medication that thins the blood to prevent blood clots), taken once daily, is able to help prevent future medical events such as a heart attack or a stroke, without increasing bleeding events, among adults who have experienced a spontaneous (non-traumatic) intracerebral haemorrhage (a type of stroke that is caused by bleeding in the brain).
By participating in this trial, survivors of intracerebral haemorrhage (ICH) will contribute to advancing knowledge about the best treatments to maintain good health for people like them. They will also be followed-up regularly during the trial, during which time they can access help with any health issues associated with their ICH and recent research advances in ICH.
What is intracerebral haemorrhage?
Intracerebral haemorrhage (brain haemorrhage) is a type of stroke, caused by bleeding into a part of the brain. It affects several million people in the world each year. Many people who survive an intracerebral haemorrhage are affected by, or at risk of, a number of diseases that can cause blood to clot in blood vessels (e.g. atherosclerosis, or hardening of the arteries) and block the supply of blood to the brain or heart. This can cause an ischaemic stroke (stroke caused by a blood clot in the brain) or a heart attack. Currently, the main way to manage this risk is to identify and treat the underlying cause of the intracerebral haemorrhage and to lower blood pressure by means of lifestyle management and/or medication.
What is antiplatelet monotherapy?
Antiplatelet therapy is a term used to describe treatment with a drug that decreases the ability of blood clots to form. These drugs include aspirin and clopidogrel. These treatments are often prescribed to people after they have experienced a heart attack or a stroke caused by a blood clot. However after a brain haemorrhage, patients and their doctors are often uncertain about whether it is beneficial to take antiplatelet medications to prevent future blood clots occurring in diseased blood vessels, or whether to avoid them in case they increase the risk of another bleed.
Previous research suggests that antiplatelet therapy may be beneficial for survivors of intracerebral haemorrhage by reducing the risk of future vascular events, including heart attack and stroke and possibly recurrence of intracerebral haemorrhage. This research project is testing whether taking or avoiding antiplatelet medication (aspirin or clopidogrel) once daily is best for overall health after intracerebral haemorrhage.
Am I eligible?
People who are 18 years old or over, and who have experienced a stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (brain haemorrhage, stroke caused by a bleed in the brain) are able to express an interest to participate in the study.
Where will this clinical trial be conducted?
This clinical trial is being coordinated from Sir Charles Gairdner Hospital (Stroke Research Unit) in Perth, Western Australia. Anybody in Australia can participate as recruitment and follow up will be managed remotely by the ASPIRING trial team in Perth. While travel to clinical sites is not required, participants will be required to book appointments with their GP to discuss eligibility.
What does participation involve?
Participation in this clinical trial involves:
Screening and baseline assessments with their GP:
- Informed consent
Assessment of key inclusion and exclusion criteria
Baseline assessments, which may include:
- A health and medical review that involves questions about demographics, lifestyle, medical history, and current medication
- Measurements of height, weight and blood pressure
- A pregnancy test (if appropriate)
- Random allocation (randomisation) to start antiplatelet monotherapy or avoid antiplatelet therapy
An initial follow-up interview at 1-month after randomisation and then at 3 and 6 months after randomisation (by phone or video call), and then every 6 months until 48 months post randomisation asking about:
Progress in the trial, including any side effects if allocated to the take antiplatelet therapy group
- Current medications and use of antithrombotic therapy
Recent blood pressure
- Any new major medical events such as heart attack or stroke